OVERVIEW

Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL is organized by PeerView Institute for Medical Education (PVI), Penn State College of Medicine and will be held from Oct 09, 2018 - Oct 08, 2019.

Target Audience:
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other healthcare professionals involved in the care of patients with B-cell malignancies.

Accreditation:
Providership, Credit, and Support:
The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Description and Educational Objectives:
In this activity, experts in non-Hodgkin lymphoma discuss the best way to utilize novel therapeutics in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or mantle cell lymphoma (MCL) while also considering prognostic factors, issues such as treatment history, and molecular features or cytogenetics. The faculty also addresses the unique safety profiles of agents such as BTK, PI3K, and Bcl-2 inhibitors, novel antibodies, and immunomodulating agents, while also describing potential future applications such as novel combination approaches in a range of B-cell cancers. This MasterClass and Tumor Board learning session features several clinical and patient scenarios that open each scientific discussion and help to illustrate how novel therapeutics are making a difference in the care of patients with CLL, FL, or MCL.

Upon completion of this activity, participants should be better able to:
• Summarize evidence on the safety and efficacy of BCR inhibitors, next-generation antibodies, immunomodulators, and other emerging strategies in the management of B-cell malignancies
• Recommend therapy with novel agents for newly diagnosed or relapsed/refractory B-cell cancers such as FL, CLL, and MCL
• Manage adverse events in patients with B-cell malignancies receiving therapy with regimens that contain novel agents

Additional details will be posted as soon as they are available.